BUTIBUFEN SODIUM

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H19O2.Na
Molecular Weight	242.2892
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CCC(C([O-])=O)C1=CC=C(CC(C)C)C=C1

InChI

InChIKey=SJBWJHOBCVAGGD-UHFFFAOYSA-M

InChI=1S/C14H20O2.Na/c1-4-13(14(15)16)12-7-5-11(6-8-12)9-10(2)3;/h5-8,10,13H,4,9H2,1-3H3,(H,15,16);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C14H19O2
Molecular Weight	219.2995
Charge	-1
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/901061 | https://nomenclator.org/medicamento/mijal-500mg-30-sobres.html | https://www.ncbi.nlm.nih.gov/pubmed/9061203

Butibufen is a non-steroidal anti-inflammatory cyclooxygenase inhibitor with analgesic and antipyretic properties. The drug was investigated for the treatment of osteoarthritis, rheumatoid artritis, and other arthroses. It was marketed under tradenames Mijal and Butilopan but now is withdrawn from the market.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10579692	Inhibitor 8504

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:38:20 GMT 2025` Edited by `admin` on `Mon Mar 31 23:38:20 GMT 2025`
Record UNII	33KW1RW80I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUTIBUFEN SODIUM

Common Name

English

BENZENEACETIC ACID, .ALPHA.-ETHYL-4-(2-METHYLPROPYL)-, SODIUM SALT (1:1)

Preferred Name

English

Code System Code Type Description

CAS

60682-24-8